JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Laropiprant (aslo known as MK-0524; Cordaptive) is a novel, potent, selective DP prostaglandin D2 (PGD2) receptor (DP) receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively. Laropiprant was once used as a drug in combination with niacin to reduce blood cholesterol (LDL and VLDL) that is no longer sold, due to increases in side-effects with no cardiovascular benefit. On April 28, 2008, the U.S. Food and Drug Administration (FDA) issued a 'not approved' letter for Cordaptive. Tredaptive was approved by the European Medicines Agency (EMA) on July 3, 2008. On January 11, 2013, Merck & Co Inc. announced they were withdrawing the drug worldwide as a result of European regulators recommendations.
References: PLoS One. 2012; 7(8):e40222; J Med Chem. 2007 Feb 22; 50(4):794-806.
Synonym: MK-0524; MK0524; MK 0524; Laropiprant. Trade name: Cordaptive, Tredaptive
Chemical Name: ((3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1, 2, 3, 4-tetrahydrocyclopenta(b)indol-3-yl)acetic acid
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!